Overview

Safety and Tolerability Study of SPN-817 in Adult Patients With Treatment Resistant Epilepsy

Status:
Not yet recruiting
Trial end date:
2025-01-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the safety and tolerability of SPN-817 in adults with treatment resistant seizures
Phase:
Phase 2
Details
Lead Sponsor:
Supernus Pharmaceuticals, Inc.
Treatments:
Huperzine A